Objective To study the effects of survivin antisense RNA on SGC7901 cell’s apoptosis and chemosensitivity to taxotere, and to investigate its effect on the expression of multi-drug resistance gene-1 (MDR-1). Methods Survivin antisense eukaryotic vector anti-pcDNA3-svv was transfected into SGC7901 cell lines by lipofectamine and positive clones were screened out then. Survivin protein and MDR-1 mRNA were measured by western blot and RT-PCR, respectively. Apoptosis that was induced by anti-pcDNA3-svv was observed by electronic microscope, and the sensitivity of SGC7901 cell to taxotere was examined by MTT. Results The expressions of survivin protein and MDR-1 mRNA in transfected SGC7901 cells both decreased more significantly than that of non-transfected cells (P＜0.05， P＜0.01), and the indices of MDR of transfection group and non-transfection group were 0.196±0.013 and 3.126±0.019, respectively, at the late phase of apoptosis, which had a significant difference between each other (P＜0.01), IC50 of the transfected cells to taxotere was （16.7±1.98） ng/ml and that of the non-transfected cells was (55.7±1.89) ng/ml, which also had a significant difference (P＜0.01). Conclusion Surivivin antisense RNA could induce the apoptosis of SGC7901 cancer cell line and could increase the cells’ sensitivity to taxotere, which may help to reverse drug resistance.
Objective To investigate nosocomial non-fermented bacterial infection in lower respiratory tract and the risk factors for multi-drug resistant bacterial infection. Methods 229 patients with nosocomial nonfermented bacterial infection in lower respiratory tract from January to December in 2007 in Xiangya Hospital were analyzed retrospectively. The distribution and drug sensitivity of pathogens were recorded. Of those 229 patients,183 cases were infected by non-fermented multi-drug resistant bacteria( MDRB) . The risk factors for non-fermented MDRB infection in lower respiratory tract were analyzed by multi-factor logistic multiple regression analysis.Results The top four non-fermented bacteria isolated were Pseudomonas aeruginosa( 47.6%) , Acinetobacter baumannii( 36. 3% ) , Acinetobacter spp( 8. 6% ) , and Stenotrophomonas maltophilia( 5. 1%) . Higher isolatated rate was found in neurosurgery ( 25. 7% ) and central ICU( 22. 9% ) . The isolated non-fermented bacteria except Stenotrophomonas maltophilia were resistant to all antibiotics except cefoperazone-sulbactam and meropenem. ICU stay( P lt; 0. 001) , tracheotomy or tracheal intubation( P = 0. 001) , and previous use of carbapenemantibiotics( P =0. 032) were independent risk factors for non-fermented MDRB infection. Conclusion Non-fermented bacillus were important pathogens of nosocomial infection in lower respiratory tract with high rates of antibiotic resistance. It is important to prevent non-fermented MDRB infection by strict limitation on the indication of ICU stay,tracheotomy and use of carbapenem.
Objective To evaluate the efficacy and safety of colistin in the treatment of severe infections. Methods PubMed, ISI Web of Knowledge and Wanfang databases were searched. The initial literatures and references listed in the literature were manually searched. Controlled studies were analyzed using RevMan 5. 0 software.Results Eleven studies were enrolled, including five prospective studies and six retrospective studies. Pooled analysis showed that, compared with other therapies, treatment with colistin in severe infections did not improve 28 or 30-day mortality, clinical symptoms, or bacteria clearance,however, increased the risk of kidney damage. Subgroup analysis showed that colistin did not improve symptoms, mortality ( which was even higher in the patients with drug resistant bacteria infection) , or kidney damage in drug resistant bacteria infections and ventilator associated pneumonia ( VAP) compared with the other antibiotic group. Conclusions Colistin is not superior to the other antibiotics in severe infections.However, there are some shortcomings in our meta-analysis due to limited high-quality RCTs, thus welldesigned RCTs are still needed before final conclusion is made.
ObjectiveTo learn the status quo and characteristics of multi-drug resistant organism (MDRO) infection in a comprehensive hospital of the first grade in Sichuan Province, analyze the effect of prevention and control intervention, in order to provide a scientific basis for clinical MDRO prevention and control. MethodsWe collected MDRO data from January to June 2014 and from January to June 2015 through multi-drug resistance reporting software, and analyzed and compared the infection of MDRO during those two time periods. Then, we evaluated the prevention and control effect of MDRO infection. ResultsThe number of inpatients from January to June 2014 was 24709, among which 813 were detected with MDRO infection. Of those infected patients, 196 had nosocomial infection of MDRO and the other 617 had community infection/colonization. The proportion of nosocomial MDRO infection was 24.10%. The MDRO nosocomial infection case rate was 0.79%. The proportion of community MDRO infection/colonization was 75.90%. The number of inpatients from January to June 2015 was 25329, and 739 of them were found with MDRO infection, of whom 132 had nosocomial infection and 607 community infection/colonization. The proportion of nosocomial MDRO infection was 17.86%. The MDRO nosocomial infection case rate was 0.52%. The proportion of community infection/colonization was 80.14%. Compared with the first half of 2014, the proportion of nosocomial MDRO infection was lower with a statistically significant difference (χ2=9.062, P<0.001), and MDRO nosocomial infection case rate was also significantly lowered (χ2=14.220, P<0.001). There were significant differences between the first half of 2015 and the same period of 2014 in hospital department distribution of MDRO infection, patient infection site distribution and pathogen detection. ConclusionThe nosocomial MDRO infection control situation of our hospital is improved after the comprehensive prevention and control interventions, and we should focus on the prevention and control of key departments, important infection sites and major resistant bacteria in the future MDRO hospital infection control work.